This satellite session will launch the JIAS supplement "Integrating services for HIV and related comorbidities: modelling to inform policy and practice." While people living with HIV (PLWH) are living longer due to antiretroviral treatment (ART), they are developing non-communicable diseases (NCDs) as they age. These NCD co-morbidities are not being diagnosed or treated in many low-and middle-income countries (LMICs). In countries with generalized HIV epidemics, a question asked is: What is the most cost effective way to implement integrated HIV/NCD care? In countries where the epidemic is concentrated within key populations, a question is: Can we integrate HIV and mental health or substance use services? To answer these questions data can be provided through mathematical modeling and surveys. This supplement highlights several examples of the use of mathematical modeling to provide data to make decisions on how to provide more comprehensive care to PLWH.

In order to end the HIV epidemic among adolescents and young adults in the US, the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) recognizes the central role that community members and youth must play in research. In this session, Manuel Ocasio will provide a window into the community of sexual and gender minority youth in New Orleans and three ATN youth representatives - Ron Smalls, Booker Shorter, and Daniel Rodriguez - will share their perspectives on methods for engaging and retaining youth in research.

Research training and capacity building in low- and middle-income countries (LMIC) have been critical to understanding and effectively preventing and treating HIV infection and AIDS. This session will highlight successes and lessons learned from training and capacity programs over the past three decades and stimulate discussion on future activities to local ownership and sustainability. The panel will feature early-career current of recent LMIC trainees as well as LMIC senior mentors and organizational heads who can talk about needs and opportunities that can be harnessed for sustained growth of the research environment. The symposium is organized by the Fogarty International Center of the U.S. National Institutes of Health, which has been supporting HIV research training for more than 30 years, and is seeking input for continued support of the research training and capacity building efforts.

This Symposium will examine the global targets for HIV such as Getting to Zero by 2030 also exploring the Sustainable Development Goals (SDGs) and how Indigenous Peoples play an important role in achieving them. Although all of the 17 SDGs are relevant for Indigenous Peoples, they are mentioned specifically in Goals 2 and 4. Ensuring that SDG implementation takes place in conformity with the United Nations Declaration on the Rights of Indigenous Peoples is essential. It is our collective responsibility to support Indigenous Peoples and, ultimately, the well-being of our planet.

HIV testing is an essential tool for epidemic control, the entry point to patient management and further prevention of transmission. Ensuring equitable access to diagnosis is paramount. HIV Self-Testing (HIVST) offers such opportunities through a variety of approaches tailored to meet the needs of priority populations. With dwindling investments in HIV programming including HIV testing, models of HIVST distribution that are independent from external investments offer options for longer-term sustainability. The STAR project in Southern Africa and the ATLAS project in West-Africa have gathered evidence through research and implementation for such models that could be replicated in other countries that are scaling up HIVST. Short Interviews with Representatives from MOHs, Researchers, Implementers, Donors and Beneficiaries and short videos of HIVST case studies from Southern Africa and West-Africa.

Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined - even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.

For nearly forty years, the National Institutes of Health (NIH) has conducted impactful, landmark HIV/AIDS research from innovative basic science discoveries through the pipeline to preclinical studies and novel clinical trials around the world. NIH-supported research is critical to reach ambitious but achievable goals to end the HIV epidemic in the United States by 2030 and HIV pandemic control globally. The satellite will highlight NIH HIV/AIDS research at the intersections of Prevention, Treatment and Disparities across the lifespan. Multidisciplinary scientists share unique insights, research findings, and experiences that will improve understanding of how the global and the domestic HIV epidemics can inform each other and accelerate epidemic control. The session aims to help build the capacity of current and future generations of HIV researchers and advocates to address 21st century challenges with 21st century solutions.

In February 2019, the U.S. Government (USG) launched Ending the HIV Epidemic: A Plan for America (EHE), an initiative working to lower the number of new HIV infections in the U.S. by 75% by 2025 and 90% by 2030. EHE prioritizes efforts in jurisdictions where most new infections occur and is founded on 4 pillars: Diagnose all individuals with HIV as early as possible after infection; Treat people with HIV rapidly and effectively to reach sustained viral suppression; Prevent new HIV transmissions by using proven interventions, including PrEP and SSPs; and Respond quickly to potential HIV outbreaks to get prevention and treatment services to people who need them. This session will feature a dialogue between USG leaders and community leaders charged with implementing EHE. The session will also include information on the USG's Ready, Set, PrEP program, a key component of EHE's Prevent pillar, which provides free PrEP medications to people who qualify.

Self-care is how individuals protect their own health, prevent disease, and treat illness, both with and without the support of a healthcare provider. Interventions such as condoms, HIV self-testing, PrEP, self-sampling for STIs, and digital solutions have led to a greater configuration of self-led HIV prevention, treatment and care possibilities than ever before. COVID-19 has accelerated and emphasized the need for self-care interventions to meet the needs of people who live with or are at risk of HIV to alleviate an already overburdened healthcare system. The accessibility of self-care is dependent on the support of governments and policymakers to ensure there is deliberate integration of self-care into health policy, program, and practice. Through this panel discussion, the speakers will explain how self-care has been an integral component of the healthcare system and integrated in HIV response, reshaping how HIV prevention, treatment and care services are provided.